Horizon Therapeutics recently announced new MRI imaging data from a phase 3 clinical trial, which demonstrated that Uplizna reduced formation of asymptomatic optic nerve lesions in patients with neuromyelitis optica spectrum disorder.
According to a company release, Uplizna (inebilizumab-cdon, Horizon) is the first and only B-cell depleting monotherapy approved by the FDA, European Commission and Brazilian Health Regulatory Agency for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+).
Nearly 80% of